Selected article for: "activity inhibitor and acute sars respiratory syndrome"
Author: Shionoya, Kaho; Yamasaki, Masako; Iwanami, Shoya; Ito, Yusuke; Fukushi, Shuetsu; Ohashi, Hirofumi; Saso, Wakana; Tanaka, Tomohiro; Aoki, Shin; Kuramochi, Kouji; Iwami, Shingo; Takahashi, Yoshimasa; Suzuki, Tadaki; Muramatsu, Masamichi; Takeda, Makoto; Wakita, Takaji; Watashi, Koichi
Title: Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor in vitro
  • Cord-id: f6nrqr1f
  • Document date: 2021_4_30
    • ID: f6nrqr1f
    Snippet: Coronavirus disease 2019 (COVID-19) has caused serious public health, social, and economic damage worldwide and effective drugs that prevent or cure COVID-19 are urgently needed. Approved drugs including Hydroxychloroquine, Remdesivir or Interferon were reported to inhibit the infection or propagation of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), however, their clinical efficacies have not yet been well demonstrated. To identify drugs with higher antiviral potency, we
    Document: Coronavirus disease 2019 (COVID-19) has caused serious public health, social, and economic damage worldwide and effective drugs that prevent or cure COVID-19 are urgently needed. Approved drugs including Hydroxychloroquine, Remdesivir or Interferon were reported to inhibit the infection or propagation of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), however, their clinical efficacies have not yet been well demonstrated. To identify drugs with higher antiviral potency, we screened approved anti-parasitic/anti-protozoal drugs and identified an anti-malarial drug, Mefloquine, which showed the highest anti-SARS-CoV-2 activity among the tested compounds. Mefloquine showed higher anti-SARS-CoV-2 activity than Hydroxychloroquine in VeroE6/TMPRSS2 and Calu-3 cells, with IC(50) = 1.28 μM, IC(90) = 2.31 μM, and IC(99) = 4.39 μM in VeroE6/TMPRSS2 cells. Mefloquine inhibited viral entry after viral attachment to the target cell. Combined treatment with Mefloquine and Nelfinavir, a replication inhibitor, showed synergistic antiviral activity. Our mathematical modeling based on the drug concentration in the lung predicted that Mefloquine administration at a standard treatment dosage could decline viral dynamics in patients, reduce cumulative viral load to 7% and shorten the time until virus elimination by 6.1 days. These data cumulatively underscore Mefloquine as an anti-SARS-CoV-2 entry inhibitor.

    Search related documents:
    Co phrase search for related documents
    • absence presence and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • absence presence and addition time: 1
    • absence presence and luciferase activity: 1, 2, 3, 4, 5
    • action different mode and addition time: 1, 2
    • action mode and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • action mode and addition time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • action mode and addition time assay: 1, 2, 3
    • action mode and low antiviral activity: 1, 2, 3, 4, 5, 6
    • action mode and luciferase activity: 1, 2
    • activity evaluate and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • activity evaluate and addition time: 1
    • acute respiratory and addition time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and addition time analysis: 1
    • acute respiratory and addition time assay: 1, 2, 3, 4
    • acute respiratory and low antiviral activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12